fda status of bpc 157 2025 FDA's Overreach on Compounded Peptides Next week, July 23-24, the
Description
2025;DOI: 10.1056/NEJMoa2502082
The safety profile was consistent with GLP-1 receptor agonists, primarily featuring transient, mild-to-moderate gastrointestinal adverse events (e.g., nausea, 55%), with low discontinuation rates (6-8.4%)
The List identifies the substances and methods prohibited in- and out-of-competition, and in particular in sports
Think of it this way: if GLP-1 agonists are turning down one volume knob on hunger, cagrilintide is reaching for a different knob entirely
Safety depends on the ingredients, your health conditions, and whos administering them
